Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW274150 in Acute Migraine
NCT00319137Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in migraine comparing GW274150 with Placebo (2 arms). Primary endpoint: Dose of GW274150 that results in 50% of subjects reporting cessation of migraine pain at 2 hours. Started Dec 2005; status: completed.
02
Drugs
GW274150
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00319137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319137.